Establishment of patient-derived esophageal squamous-cell carcinoma xenograft in mice and characteristics of signaling pathways related to proliferation in SCID mice

AIM: To establish and characterize the patient-derived esophageal squamous-cell carcinoma xenograft (PDECX) in mice. METHODS: The samples of human esophageal cancer were grafted into severe combined immunodeficient (SCID) mice. The xenografts were transferred to SCID mice when the first passage of xenografts grew up. The growth of tumors in the first, second and third passages was observed. HE staining was performed. The expression of CK5/6, p63 and p40 in the patient samples, and the first and third passages of the xenografts were detected by immunohistochemical analysis. The expression of mTOR, p-mTOR, p70S6K, p-p70S6K, Akt1, p-Akt (Ser473), Erk1/2 and p-Erk1/2 were determined by Western blot.RESULTS: The PDECX was successfully established. The positive expression of CK5/6, p63 and p40 in the xenografts was consistent with that in the patients' samples. The levels of phosphorylated and total proteins of proliferation-related signaling pathways were different in the xenografts from different patients.CONCLUSION: The PDECX model adequately reflects the tumal heterogeneity that is observed in the patients.